SCHEMBL8551963

SCHEMBL8551963

NC(=O)c1sc(Cl)nc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPT P10636 4/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
AHR P35869 1/20 0.38
CDK8 P49336 1/20 0.36
CDK19 Q9BWU1 1/20 0.36
P2RY1 P47900 1/20 0.35
POLB P06746 1/20 0.35
LIMK1 P53667 3/20 0.34
HTT P42858 2/20 0.33
RAB9A P51151 1/20 0.33
KDM4E B2RXH2 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ATF1 P18846 1/20 0.31
NFKB1 P19838 1/20 0.31
F2 P00734 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrazine SCHEMBL9675518 0.85 ALDH1A1 (0.52) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL1778181 0.85 ALDH1A1 (0.55) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL2310145 0.83 MEN1 (0.49) MEN1KMT2AMAPTALDH1A1HPGD
Hydrochloric Acid SCHEMBL10820945 0.83 ALDH1A1 (0.53) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL10712503 0.81 MEN1 (0.48) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL20782306 0.81 MEN1 (0.42) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL24725746 0.81 MEN1 (0.45) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL9674877 0.81 MEN1 (0.54) MEN1KMT2AMAPTALDH1A1HPGD
Isopropylamine SCHEMBL10821400 0.80 ALDH1A1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL20782350 0.79 CDK8 (0.37) MEN1KMT2AMAPTALDH1A1CDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104163791-B N-pyridine (hetero) aryl amide compound and preparation method and application thereof 湖南化工研究院 2017-05-03 CN claimed
EP-0279239-B1 MICROBICIDES CIBA-GEIGY AG (CH) 1992-11-11 EP claimed
US-20250339541-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-11-06 US disclosed
US-20250223280-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-07-10 US disclosed
US-20250213699-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-07-03 US disclosed
US-12290568-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2025-05-06 US disclosed
US-12280116-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2025-04-22 US disclosed
US-20240424108-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-12-26 US disclosed
US-12128106-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2024-10-29 US disclosed
US-20240307546-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-09-19 US disclosed
US-12076408-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2024-09-03 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20230097256-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2023-03-30 US disclosed
EP-4097138-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS Avila Therapeutics, Inc. (US) 2022-12-07 EP disclosed
WO-2022235699-A2 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed
CN-115066438-A ASGPR binding compounds for degrading extracellular proteins 阿维拉治疗公司 2022-09-16 CN disclosed
WO-2021155317-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2021-08-05 WO disclosed
CN-104163791-B N-pyridine (hetero) aryl amide compound and preparation method and application thereof 湖南化工研究院 2017-05-03 CN disclosed
EP-0566138-B1 Amino thiazole derivatives and their use as fungicides HODOGAYA CHEMICAL CO LTD (JP) 1998-11-18 EP disclosed
EP-0566138-A1 Amino thiazole derivatives and their use as fungicides HODOGAYA CHEMICAL CO., LTD. (JP) 1993-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885
US-20250339541-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885
US-20240424108-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885
US-20250213699-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885
US-20250223280-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B MEN1 4089/4885KMT2A 4639/4885MAPT 4090/4885
US-20230097256-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885
US-12076408-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885
US-12128106-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885
US-12290568-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885
US-12280116-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885
US-20240307546-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS ASGR1, ENGASE, FCGR2A MEN1 3647/4885KMT2A 4789/4885MAPT 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.